AzurRx BioPharma Inc (NASDAQ:AZRX) Receives $7.58 Average Target Price from Brokerages
Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.58.
AZRX has been the topic of a number of research analyst reports. National Securities initiated coverage on AzurRx BioPharma in a research note on Tuesday, June 11th. They issued a “buy” rating and a $9.00 price target on the stock. Maxim Group reissued a “buy” rating and issued a $315.00 price target (up from $305.00) on shares of Domino’s Pizza in a research note on Wednesday, April 24th. Finally, HC Wainwright set a $3.00 price target on McEwen Mining and gave the stock a “buy” rating in a research note on Friday, May 24th.
NASDAQ:AZRX traded up $0.10 during mid-day trading on Friday, reaching $1.05. The company’s stock had a trading volume of 625,668 shares, compared to its average volume of 251,481. The stock’s fifty day moving average price is $1.64. AzurRx BioPharma has a twelve month low of $0.91 and a twelve month high of $3.75.
Institutional investors have recently added to or reduced their stakes in the company. Waldron Private Wealth LLC purchased a new position in shares of AzurRx BioPharma in the 1st quarter worth about $169,000. 683 Capital Management LLC raised its holdings in shares of AzurRx BioPharma by 73.9% in the 4th quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock worth $842,000 after purchasing an additional 295,504 shares during the period. Finally, Regentatlantic Capital LLC purchased a new position in shares of AzurRx BioPharma in the 1st quarter worth about $48,000. Institutional investors own 13.12% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Article: What is a recession?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.